Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451018 | 1.00 | GHSR (0.67) | GHSR | |
| SCHEMBL29405176 | 0.99 | GHSR (0.68) | GHSR | |
| SCHEMBL29405001 | 0.99 | GHSR (0.68) | GHSR | |
| SCHEMBL30438610 | 0.98 | GHSR (0.67) | GHSR | |
| SCHEMBL30169433 | 0.97 | GHSR (0.68) | GHSR | |
| SCHEMBL29973452 | 0.96 | GHSR (0.67) | GHSR | |
| SCHEMBL29619357 | 0.96 | GHSR (0.64) | GHSR | |
| SCHEMBL29472045 | 0.96 | GHSR (0.64) | GHSR | |
| SCHEMBL30633854 | 0.96 | GHSR (0.67) | GHSR | |
| SCHEMBL29577125 | 0.95 | GHSR (0.68) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527423-B | Euphausia superba oligopeptide for adjuvant therapy of NAFLD and application thereof | 浙江海洋大学 | 2023-03-07 | — | — | CN | claimed |
| CN-113527423-B | Euphausia superba oligopeptide for adjuvant therapy of NAFLD and application thereof | 浙江海洋大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-113527423-B | Euphausia superba oligopeptide for adjuvant therapy of NAFLD and application thereof | 浙江海洋大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-109180803-B | Somatostatin and preparation method and pharmaceutical composition thereof | 成都天台山制药有限公司 | 2022-02-08 | — | — | CN | disclosed |